Immutep Limited filings document foreign private issuer current reports for a clinical-stage biotechnology company focused on cancer and autoimmune diseases. Its Form 6-K disclosures include ASX activity reports, Appendix 4C cash-flow materials, clinical-program updates, research collaboration announcements, and liquidity information.
The filing record describes eftilagimod alfa development, the discontinued TACTI-004 Phase III study in first-line non-small cell lung cancer, IMP761 Phase I disclosures, Independent Data Monitoring Committee communications, and the company’s reporting framework as a Form 20-F filer.
IMMUTEP Ltd Chief Operating Officer Deanne Diem Miller reported her initial ownership on a Form 3. She directly holds 2,867,305 Ordinary Shares. In addition, she holds 1,800,000 performance rights, each giving a right to receive Ordinary Shares at an exercise price of $0.0000 per share.
These performance rights are structured in three equal tranches of 600,000 underlying Ordinary Shares each, scheduled to vest on December 1, 2026, December 1, 2027, and December 1, 2028. Vesting of the later tranches depends on Ms. Miller achieving specified key performance indicators at the applicable vesting dates.
IMMUTEP Ltd director Pete A. Meyers filed an initial ownership report showing both ordinary shares and performance rights. He holds 4,052,173 Ordinary Shares directly. In addition, he holds performance rights over blocks of 388,889, 758,631, 650,000, and 650,000 underlying Ordinary Shares at an exercise price of $0.0000 per share.
The footnotes state these performance rights were granted on December 16, 2022 and December 2, 2025. Vesting dates run from October 1, 2026 through December 1, 2029, and each grant is dependent on Mr. Meyers meeting specified vesting conditions, with expiration dates extending to December 2, 2030.
IMMUTEP Ltd Chief Medical Officer Stephan Karel Gerard Winckels filed an initial ownership report showing his equity position. He directly holds 92,935 Ordinary Shares and three blocks of 221,708 performance rights each over Ordinary Shares, with vesting dates in 2026, 2027 and 2028 and an exercise price of $0.0000. The vesting of these performance rights depends on achieving specified key performance indicators and they expire in 2030.
IMMUTEP Ltd director Frederic Joseph Daniel Triebel has filed an initial statement of beneficial ownership. The filing shows direct holdings of Ordinary Shares, including 11,353,764 shares in one entry and 170,610 shares in another, which are represented by American Depositary Shares.
The filing also lists performance rights over Ordinary Shares with a zero exercise price. Footnotes state that blocks of 900,000 performance rights are scheduled to vest on December 1 of 2026, 2027 and 2028, with additional performance rights vesting only if Dr. Triebel meets specified key performance indicators at each applicable vesting date.
IMMUTEP Ltd director Dr. Russell Howard has filed an initial Form 3 showing his equity interests in the company. The filing reports performance rights over 50,000 Ordinary Shares granted on November 23, 2023, which may vest on December 1, 2026 if vesting conditions are met. Additional performance rights granted on December 2, 2025 cover 400,154 Ordinary Shares scheduled to vest on December 1, 2026, and two further tranches of 461,746 performance rights each that may vest on December 1, 2027 and December 1, 2028, all subject to specified vesting conditions. The Form 3 also reports 1,717,977 Ordinary Shares held indirectly through Regulus Star Pty Ltd.
IMMUTEP Ltd Chief Development Officer Christian Mueller filed an initial ownership report showing he directly holds 3,774,048 Ordinary Shares. This Form 3 establishes his baseline equity position as a company officer.
Mueller also holds three tranches of performance rights over 1,400,000 Ordinary Shares in total, each with a zero exercise price. Footnotes state 466,667 performance rights are scheduled to vest on December 1, 2026 and another 466,667 on December 1, 2027, while 466,666 are scheduled to vest on December 1, 2028. Vesting of the latter two tranches depends on him achieving specified key performance indicators at each applicable vesting date.
Immutep Limited reported that the Independent Data Monitoring Committee for its TACTI-004 Phase III trial in first-line non-small cell lung cancer has recommended discontinuing the study after a planned interim futility analysis. Enrolment will stop and the company will wind down the trial with patient follow up and site close out.
The study tested eftilagimod alfa in combination with pembrolizumab and chemotherapy versus pembrolizumab, chemotherapy and placebo, targeting about 756 patients across more than 150 sites in over 25 countries. Following the discontinuation, Immutep now anticipates its cash runway will extend well beyond its prior Q2 CY2027 guidance and plans to reassess capital allocation once data review is complete.
Immutep Limited submitted a Form 6-K as a foreign private issuer, mainly to furnish an exhibit describing a new research collaboration. The exhibit, titled “Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti,” indicates that the company and the George Washington University Cancer Center plan to evaluate neoadjuvant Efti in a cancer setting. This Form 6-K serves as the formal vehicle to provide that collaboration announcement to investors and regulators.